selegiline has been researched along with Dyskinesia, Drug-Induced in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.53) | 18.7374 |
| 1990's | 8 (42.11) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 1 (5.26) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoshino, N; Ishikawa, T; Muraoka, S; Nishimura, T; Okano, M; Satoyoshi, H; Takahata, K; Tsunekawa, H | 1 |
| Choudhury, ME; Kubo, M; Nagai, M; Nishikawa, N; Nomoto, M; Yabe, H | 1 |
| Iida, Y; Saji, H | 1 |
| Hauser, RA; Hubble, JP; Truong, DD | 1 |
| Hollán, S; Magyar, K; Vécsei, L | 1 |
| Kurlan, R | 1 |
| Waters, C | 1 |
| Ludolph, A; Odin, P; Oehlwein, C; Polzer, U; Renner, R; Schüler, P; Shing, M; Storch, A; Werner, G | 1 |
| Weiner, M | 1 |
| Imai, T; Nakamura, Y; Ogawa, N; Tachibana, H; Takahashi, M; Yorifuji, S; Yuasa, R | 1 |
| Amico, ET; Ciraulo, DA; Dreyfuss, DA; Goff, DC; Renshaw, PF; Sarid-Segal, O | 1 |
| Tolosa, E; Valldeoriola, F | 1 |
| Oertel, WH; Quinn, NP | 1 |
| Ahlskog, JE | 1 |
| Cathcart, S; Sachdev, P; Saharov, T | 1 |
| Ben-Shlomo, Y; Head, J; Katzenschlager, R; Lees, AJ | 1 |
| Lander, CM; Lees, A; Stern, G | 1 |
| Marsden, CD | 1 |
| Ahlskog, JE; Wilkinson, JM | 1 |
7 review(s) available for selegiline and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
[Biomedical imaging in pharmacology with nuclear medical imaging methodologies: positron emission tomography (PET) and single photon emission computed tomography (SPECT)].
Topics: Alzheimer Disease; Animals; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Parkinson Disease; Selegiline; Synaptic Transmission; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2003 |
Other pharmacological treatments for motor complications and dyskinesias.
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Dyskinesia, Drug-Induced; Gait; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Periodicity; Purinergic P1 Receptor Antagonists; Purines; Selegiline | 2005 |
Update on antiparkinsonian agents.
Topics: Aged; Amantadine; Antiparkinson Agents; Blood-Brain Barrier; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Gastrointestinal Diseases; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Receptors, Dopamine; Selegiline; Vascular Resistance | 1982 |
Mid-stage parkinsonism with mild motor fluctuations.
Topics: Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Dopamine Agonists; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 1994 |
Parkinson's disease: drug therapy.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Cholinergic Antagonists; Dopamine Agonists; Dyskinesia, Drug-Induced; Guidelines as Topic; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Treatment Outcome | 1997 |
Medical treatment of later-stage motor problems of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease, Secondary; Propranolol; Randomized Controlled Trials as Topic; Selegiline; Tolcapone | 1999 |
Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Adrenal Glands; Adult; Antiparkinson Agents; Brain Chemistry; Child; Child, Preschool; Cytoplasmic Granules; Dyskinesia, Drug-Induced; Environmental Pollutants; Fetus; Humans; Levodopa; Middle Aged; Palliative Care; Parkinson Disease; Prevalence; Research; Selegiline; Substantia Nigra; Time Factors | 1990 |
5 trial(s) available for selegiline and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
Topics: Adenosine A2 Receptor Antagonists; Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Chronic Disease; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Nausea; Parkinson Disease; Purines; Safety; Selegiline; Treatment Outcome | 2003 |
Efficacy and safety of high-dose cabergoline in Parkinson's disease.
Topics: Adolescent; Adult; Aged; Amantadine; Antiparkinson Agents; Cabergoline; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Humans; Levodopa; Middle Aged; Nitriles; Parkinson Disease; Piperidines; Prospective Studies; Quality of Life; Selegiline; Severity of Illness Index; Treatment Outcome | 2006 |
Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial.
Topics: Aged; Chi-Square Distribution; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline | 1994 |
A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Free Radicals; Humans; Lipid Peroxidation; Male; Middle Aged; Neurologic Examination; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Selegiline | 1993 |
Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial.
Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Bromocriptine; Disability Evaluation; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Incidence; Levodopa; Male; Parkinson Disease; Selegiline; Treatment Outcome | 2001 |
7 other study(ies) available for selegiline and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Topics: Animals; Antiparkinson Agents; Benserazide; Cytoskeletal Proteins; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Movement; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger; Selegiline; Time Factors | 2018 |
Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anticonvulsants; Biogenic Amines; Brain Chemistry; Callithrix; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Homovanillic Acid; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neostriatum; Neurons; Selegiline; Zonisamide | 2009 |
Adverse effects of dopamine potentiation by long-term treatment with selegiline.
Topics: Adolescent; Adult; Anemia, Hemolytic, Congenital; Antiparkinson Agents; Baclofen; Basal Ganglia; Basal Ganglia Diseases; Blood Platelets; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia Musculorum Deformans; Female; Genetic Carrier Screening; Genotype; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Huntingtin Protein; Long-Term Care; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Tissue Proteins; Neurologic Examination; Neuroprotective Agents; Nuclear Proteins; Polymerase Chain Reaction; Proteins; Psychoses, Substance-Induced; Reference Values; Selegiline; Trinucleotide Repeats | 2004 |
"Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease.
Topics: Aged; Amantadine; Benzothiazoles; Catechols; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Humans; Iatrogenic Disease; Indoles; Levodopa; Male; Middle Aged; Neurology; Neuropharmacology; Neurotoxicity Syndromes; Nitriles; Parkinson Disease; Pramipexole; Selegiline; Thiazoles; Treatment Outcome | 2005 |
The preventative role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia.
Topics: Animals; Antioxidants; Antipsychotic Agents; Delayed-Action Preparations; Disease Models, Animal; Dyskinesia, Drug-Induced; Fluphenazine; Free Radicals; Male; Neuroprotective Agents; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Selegiline; Vitamin E | 1999 |
Oscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenyl.
Topics: Bromocriptine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1979 |
New concepts in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Diet; Dopamine Agents; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Intestinal Absorption; Levodopa; Parkinson Disease; Selegiline | 1990 |